Search > Throat Cancer
My employer runs this trial

STRO-006 for Cancer

Not yet recruiting at 6 trial locations
SC
Overseen BySutro Clinical Team
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Sutro Biopharma, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts:

* Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of STRO-006.

* Part 1B is a dose expansion in one or more indications, as determined by the Sponsor, to further evaluate a STRO-006 monotherapy dose, examine anti-tumor activity, and determine the recommended Phase 2 dose (RP2D) of STRO-006 monotherapy.

* Part 1C is a combination dose escalation to determine safety, tolerability, PK, and preliminary anti-tumor activity of STRO-006 combined with pembrolizumab.

Who Is on the Research Team?

JO

Jennifer Oliver

Principal Investigator

Sutro Biopharma

Are You a Good Fit for This Trial?

This trial is for adults with advanced or recurring solid tumors (like lung, esophageal, colorectal, endometrial, bladder, breast, stomach, or throat cancer) that have not responded to standard treatments. Participants must be in generally stable health aside from their cancer.

Inclusion Criteria

Life expectancy of at least 3 months
Willingness and ability to comply with the study protocol and long-term follow-up (LTFU) assessments
I can join regardless of how many treatments I've had before.
See 8 more

Exclusion Criteria

Concurrent participation in another therapeutic treatment trial
I have had a solid organ or bone marrow transplant.
I have untreated or active cancer that has spread to my brain or spinal fluid.
See 6 more

What Are the Treatments Tested in This Trial?

Interventions

  • Pembrolizumab
  • STRO-006

Trial Overview

Researchers are testing a new drug called STRO-006 alone and in combination with pembrolizumab to find the safest dose and see how well it works against certain cancers. The study has several parts focusing on safety and early signs of effectiveness.

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: Part 1C STRO-006 in combination with pembrolizumabExperimental Treatment2 Interventions
Group II: Part 1B STRO-006 monotherapyExperimental Treatment1 Intervention
Group III: Part 1A STRO-006 monotherapyExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sutro Biopharma, Inc.

Lead Sponsor

Trials
7
Recruited
1,100+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.